Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study

Table 4

Multivariate logistic regression of HBsAg reduction >1 log₁₀ IU/mL at 48 weeks.

Predictors	Univariate analysis		Multivariate analysis
	OR (95% CI)		OR (95% CI)
Age (years)	0.858 (0.780–0.944)	0.002
Age > 40 years	22.812 (2.492–208.817)	0.006
BMI (kg/cm^2)	0.753 (0.479–1.183)	0.218
HBeAg-positive	0.405 (0.068–2.418)	0.322
NAs-experienced	0.340 (0.059–1.953)	0.226
PegIFNα plus NTs	29.231 (3.155–270.801)	0.003	36.667 (3.837–350.384)	0.002
PegIFNα plus NSs	1.181 (0.129–10.774)	0.883
Week of PegIFNα adding NAs (week)	0.992 (0.931–1.058)	0.813
Weeks of NAs before adding PegIFNα (week)	1.003 (0.992–1.015)	0.565
Total weeks of combination (week)	1.004 (0.942–1.070)	0.909
HBeAg at baseline (s/co)	1.001 (0.999–1.004)	0.263
ALT at baseline (U/L)	1.007 (0.995–1.018)	0.259
ALT > ULN	4.720 (0.812–27.452)	0.084
ALT at week 12 (U/L)	1.025 (0.993–1.058)	0.124
HBsAg at baseline (IU/mL)	3.338 (1.479–7.533)	0.004
HBsAg > 250 IU/mLat baseline	5.857 (0.908–37.798)	0.063
HBsAg at week 12 (IU/mL)	1.000 (1.000–1.001)	0.362
HBsAg at week 24 (IU/mL)	1.000 (1.000–1.001)	0.310
HBsAg decline at week 12 (log10 IU/mL)	0.813 (0.507–1.303)	0.390
HBsAg decline at week 24 (log10 IU/mL)	0.538 (0.310–0.932)	0.027
HBV DNA at baseline (log10 IU/mL)	1.317 (0.837–2.074)	0.234
HBV DNA at week 12 (log10 IU/mL)	1.000 (1.000–1.000)	0.543
HBV DNA decline at week 12 (log10 IU/mL)	0.905 (0.749–1.093)	0.300
WBC (×10^9/L)	0.910 (0.451–1.836)	0.792
NEUT (%)	0.962 (0.874–1.058)	0.420
RBC (×10^9/L)	1.959 (0.394–9.734)	0.411
HGb (g/L)	0.966 (0.898–1.039)	0.350
PLT (×10^9/L)	1.024 (1.001–1.048)	0.037		0.040
ALB (U/L)	1.055 (0.793–1.404)	0.711
AST (U/L)	1.018 (0.985–1.051)	0.293
GGT (U/L)	1.023 (0.963–1.086)	0.461
TBIL (μmol/L)	1.020 (0.888–1.172)	0.779

ADV, adefovir dipivoxil; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; ETV, entecavir; GGT, gamma glutamyl transferase; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HGb, hemoglobin; NEUT, neutrophils; NAs, nucleos(t)ide analogues; NEUT, neutrophils; NSs, nucleoside analogues; NTs, nucleotide analogues; PegIFNα, PEGylated interferon α; PLT, platelet; RBC, red blood cells; TBIL, total bilirubin; TDF, tenofovir disoproxil fumarate; ULN, upper limit of normal; WBC, white blood cells.